OncLive is a web resource for physicians and other health professionals focused on the treatment of cancer. The source features peer-reviewed original medical journal articles, video interviews, panel discussions, major medical conference coverage, daily medical news and serves as the website for several oncology-focused magazines. All content in OncLive is free and does not require any registration.

Wikipedia
Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting. Selinexor is an interesting new drug t...

Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma. Immune checkpoint inhibitors are very important in the treatment of cancer, not just lymphomas...

Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Having CLL, whether or not is has been treated, puts people at risk for se...

Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation. This is a very challenging area, because patients have limited options, Davids says. Overall survival is typically poo...

Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Debu Tripathy, MD, professor and chairman of the Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, discusses key takeaway points from the MONALEESA-7 trial, which was presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). The trial tested the efficacy of ribociclib (Kisqali), a CDK4/6 inhibitor, and temporary ovarian suppression in pre- and perimeno...

Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial. The SOFT trial was examining the outcomes of adding ovarian suppression to tamoxifen in patients with hormone receptor (HR)-positive breast cancer. Long-term data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) and, according t...

Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses some questions that remain after the recent phase II MEDIOLA trial. The trial, which was presented at the 2017 San Antonio Breast Cancer Symposium, showed that the combination of olaparib (Lynparza), a PARP inhibitor, and durvalumab (Imfinzi), an immunotherapy agent, could be a promising option for patients wit...

Intellisphere Oncology Specialty Group
Intellisphere Oncology Specialty Group
YouTube Video
  • Halle Moore, MD, medical oncologist, the Cleveland Clinic, discusses the use of GnRH agonists to preserve ovarian function and fertility in women with breast cancer. Moore presented the results of the POEMS study at the 2017 San Antonio Breast Cancer Symposium (SABCS), which demonstrated that when given alongside chemotherapy, goserelin, a gonadotropin-releasing hormone (GnRH) agonist, improved ...

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

By signing up, you agree to the Terms of Service and Privacy Policy.

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in

By signing up, you agree to the Terms of Service and Privacy Policy.